Markus Hovd
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Markus Hovd has a total of 130 co-authors. Here are the top co-authors by number of shared publications:
- Anders Åsberg
Department of Pharmacy University of Oslo Oslo Norway
5 shared publications - Per Kristian Eide
Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway
5 shared publications Anders Åsberg
Department of Transplantation Medicine, Oslo University Hospital-Rikshospitalet, Oslo, Norway; Norwegian Renal Registry, Oslo University Hospital-Rikshospitalet, Oslo, Norway; Department of Pharmacy, University of Oslo, Oslo, Norway
3 shared publications- Geir Ringstad
Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway
3 shared publications Hege Christensen
Department of Pharmacy University of Oslo Oslo Norway
3 shared publications- Ida Robertsen
Department of Pharmacy University of Oslo Oslo Norway
3 shared publications
Latest Publications
- Open Access
- 29 October 2026
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 21 (10) , e0360617
Understanding Glymphatic’s Role In Proteinopathies (GRIP): A single centre case-control study protocol
Alzheimer’s disease (AD), Parkinson’s disease (PD), and dementia with Lewy bodies (DLB) are proteinopathies characterized by pathological accumulation of amyloid beta, phosphorylated-tau, and alpha-synuclein. Impaired clearance of these proteins is thought to contribute to disease pathogenesis, whereas preserved or enhanced clearance may be compensatory. Beyond intracellular degradation within neurons and glial cells, an extracellular clearance pathway, the glymphatic system, facilitates cerebrospinal fluid flow into perivascular spaces, exchange with interstitial fluid, and subsequent clearance from the brain. Glymphatic transport may therefore be critical for removal of excess proteins and metabolic waste, and its dysfunction could promote protein aggregation and neurodegeneration. The Glymphatic’s Role In Proteinopathies (GRIP) study is an observational case-control imaging and biomarker study comparing glymphatic clearance in patients with AD, PD, and DLB versus healthy controls. We aim to recruit 70 participants: PD (n = 20), DLB (n = 10), AD (n = 20), and age- and sex-matched healthy controls (n = 20). The AD group will be stratified by pathology, with half amyloid-positive/tau-negative (A + T-) and half amyloid- and tau-positive (A + T+). The PD group will be stratified by disease duration. Participants will undergo baseline MRI followed by intrathecal injection of gadobutrol (0.25 mmol) and serial MRI at 5, 24, 48, and 72 hours. Influx and efflux of tracer will be modeled from T1 signal changes. Blood will be sampled repeatedly from 1 to 72 hours; cerebrospinal fluid will be collected at baseline. Individual glymphatic clearance will be estimated using population pharmacokinetic methods, where gadobutrol serves as a tracer. Sleep will be monitored with triaxial accelerometry and sleep diaries. The primary outcome is group differences in glymphatic clearance metrics between each disease group and controls; secondary analyses will explore associations with cognition, disease severity and duration, sleep quality, and cerebrospinal fluid protein levels.
- 29 October 2026
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 21 (10) , e0360617
Open AccessUnderstanding Glymphatic’s Role In Proteinopathies (GRIP): A single centre case-control study protocol
Alzheimer’s disease (AD), Parkinson’s disease (PD), and dementia with Lewy bodies (DLB) are proteinopathies characterized by pathological accumulation of amyloid beta, phosphorylated-tau, and alpha-synuclein. Impaired clearance of these proteins is thought to contribute to disease pathogenesis, whereas preserved or enhanced clearance may be compensatory. Beyond intracellular degradation within neurons and glial cells, an extracellular clearance pathway, the glymphatic system, facilitates cerebrospinal fluid flow into perivascular spaces, exchange with interstitial fluid, and subsequent clearance from the brain. Glymphatic transport may therefore be critical for removal of excess proteins and metabolic waste, and its dysfunction could promote protein aggregation and neurodegeneration. The Glymphatic’s Role In Proteinopathies (GRIP) study is an observational case-control imaging and biomarker study comparing glymphatic clearance in patients with AD, PD, and DLB versus healthy controls. We aim to recruit 70 participants: PD (n = 20), DLB (n = 10), AD (n = 20), and age- and sex-matched healthy controls (n = 20). The AD group will be stratified by pathology, with half amyloid-positive/tau-negative (A + T-) and half amyloid- and tau-positive (A + T+). The PD group will be stratified by disease duration. Participants will undergo baseline MRI followed by intrathecal injection of gadobutrol (0.25 mmol) and serial MRI at 5, 24, 48, and 72 hours. Influx and efflux of tracer will be modeled from T1 signal changes. Blood will be sampled repeatedly from 1 to 72 hours; cerebrospinal fluid will be collected at baseline. Individual glymphatic clearance will be estimated using population pharmacokinetic methods, where gadobutrol serves as a tracer. Sleep will be monitored with triaxial accelerometry and sleep diaries. The primary outcome is group differences in glymphatic clearance metrics between each disease group and controls; secondary analyses will explore associations with cognition, disease severity and duration, sleep quality, and cerebrospinal fluid protein levels.
- Open Access
- 18 August 2026
- Published by The Open Journal in Journal of Open Source Software
- Vol. 11 (124)
pharmsol: A high-performance Rust library for pharmacokinetic and pharmacodynamic modeling and simulation
- 18 August 2026
- Published by The Open Journal in Journal of Open Source Software
- Vol. 11 (124)
Open Accesspharmsol: A high-performance Rust library for pharmacokinetic and pharmacodynamic modeling and simulation
- Open Access
- 29 June 2026
- Published by SAGE Publications in Journal of Cerebral Blood Flow & Metabolism
EXPRESS: Ventricular CSF-to-blood water transport kinetics in adult hydrocephalus
Water exchange between cerebrospinal fluid (CSF) and blood is fundamental to brain fluid homeostasis, yet ventricular CSF-to-blood water transport has never been quantified as a physiological parameter in adult humans. We investigated ventricular water absorption kinetics in 40 adults undergoing diagnostic evaluation for hydrocephalus. During ventricular infusion testing, 15O-labelled water was administered intraventricularly via an external ventricular drain, with continuous jugular bulb blood sampling and simultaneous intracranial pressure (ICP) monitoring. Ventricular water absorption was estimated using non-parametric population pharmacokinetic modelling of venous radioactivity–time curves. Model performance demonstrated robust individual parameter estimation. Ventricular water absorption showed substantial inter-individual variability (mean half-time 65.2 ± 34.3 s; range 31.5–196.8 s). Absorption kinetics were not associated with static or pulsatile ICP metrics (overnight or during infusion), ventricular volume or surface area, or CSF–blood osmotic gradients. No associations were observed with demographic variables. A modest positive association was detected with the CSF–blood protein concentration difference. These findings establish ventricular CSF-to-blood water transport as a quantifiable physiological metric in adult hydrocephalus and suggest that ventricular water exchange is regulated independently of global intracranial pressure and ventricular morphology, consistent with intrinsic barrier and microvascular exchange mechanisms.
- 29 June 2026
- Published by SAGE Publications in Journal of Cerebral Blood Flow & Metabolism
Open AccessEXPRESS: Ventricular CSF-to-blood water transport kinetics in adult hydrocephalus
Water exchange between cerebrospinal fluid (CSF) and blood is fundamental to brain fluid homeostasis, yet ventricular CSF-to-blood water transport has never been quantified as a physiological parameter in adult humans. We investigated ventricular water absorption kinetics in 40 adults undergoing diagnostic evaluation for hydrocephalus. During ventricular infusion testing, 15O-labelled water was administered intraventricularly via an external ventricular drain, with continuous jugular bulb blood sampling and simultaneous intracranial pressure (ICP) monitoring. Ventricular water absorption was estimated using non-parametric population pharmacokinetic modelling of venous radioactivity–time curves. Model performance demonstrated robust individual parameter estimation. Ventricular water absorption showed substantial inter-individual variability (mean half-time 65.2 ± 34.3 s; range 31.5–196.8 s). Absorption kinetics were not associated with static or pulsatile ICP metrics (overnight or during infusion), ventricular volume or surface area, or CSF–blood osmotic gradients. No associations were observed with demographic variables. A modest positive association was detected with the CSF–blood protein concentration difference. These findings establish ventricular CSF-to-blood water transport as a quantifiable physiological metric in adult hydrocephalus and suggest that ventricular water exchange is regulated independently of global intracranial pressure and ventricular morphology, consistent with intrinsic barrier and microvascular exchange mechanisms.
- 26 June 2026
- Published by The R Foundation
egfr: Estimated Glomerular Filtration Rate (eGFR) Calculators
- 26 June 2026
- Published by The R Foundation
egfr: Estimated Glomerular Filtration Rate (eGFR) Calculators
- 5 June 2026
- Published by Wolters Kluwer Health in Journal of Clinical Psychopharmacology
Effect of Fluvoxamine Comedication on the Formation of Clozapine Metabolites Associated With Clinical Effect or Toxicity in Smoking and Nonsmoking Patients
Background: Fluvoxamine (FLU) comedication increases clozapine (CLZ) exposure and lowers dose requirements by inhibiting its metabolism. Formation of N -desmethylclozapine (DCL), CLZ- N -oxide (NOX), and reactive nitrenium ions (CYS-conjugates) has been associated with cognitive function, cardiac damage, and granulocyte toxicity, respectively. This study explored how FLU affects the formation of these CLZ metabolites in smokers and non-smokers separately. Methods: The study used therapeutic drug monitoring (TDM) data from 302 patients (52% smokers) concurrently using FLU (n = 19) or CLZ without FLU (controls; n = 283) performed during January 2019 to October 2023. Serum CLZ and DCL levels were measured during routine TDM, while NOX and CYS-conjugates were obtained by reprocessing UHPLC-HRMS data. Concentration-to-dose ratio (CD; exposure) of CLZ and metabolic ratios (MR; formation) were compared using multivariate linear regression, stratified by smoking status and adjusted for age, sex, and sampling time. Results: Smoking patients comedicated with FLU showed a 3.2-fold higher CLZ CD ratio ( P < 0.0001) and reduced formation of DCL (-38%, P < 0.0001), NOX (-49%, P < 0.0001), CLZ-8-CYS 1+ (-43%, P = 0.0103), and NOX-CYS 1+ (-62%, P = 0.003) compared with smokers receiving CLZ alone. In non-smokers, FLU treatment led to a higher CLZ CD ratio (2.6-fold, P = 0.0012) and reduced formation of DCL (-42%, P = 0.0007), NOX (-52%, P = 0.0009), and NOX-CYS 1+ (-73%, P = 0.0073) compared with the non-smoking controls. Conclusions: This study shows that FLU increases CLZ exposure regardless of smoking status and significantly reduces the formation of metabolites that have been linked to cognition, metabolic side effects, myocarditis, and granulocyte toxicity. Whether FLU alters these clinical outcomes by reducing the metabolic formation needs to be investigated further in controlled studies with access to data on treatment efficacy and side effects.
- 5 June 2026
- Published by Wolters Kluwer Health in Journal of Clinical Psychopharmacology
Effect of Fluvoxamine Comedication on the Formation of Clozapine Metabolites Associated With Clinical Effect or Toxicity in Smoking and Nonsmoking Patients
Background: Fluvoxamine (FLU) comedication increases clozapine (CLZ) exposure and lowers dose requirements by inhibiting its metabolism. Formation of N -desmethylclozapine (DCL), CLZ- N -oxide (NOX), and reactive nitrenium ions (CYS-conjugates) has been associated with cognitive function, cardiac damage, and granulocyte toxicity, respectively. This study explored how FLU affects the formation of these CLZ metabolites in smokers and non-smokers separately. Methods: The study used therapeutic drug monitoring (TDM) data from 302 patients (52% smokers) concurrently using FLU (n = 19) or CLZ without FLU (controls; n = 283) performed during January 2019 to October 2023. Serum CLZ and DCL levels were measured during routine TDM, while NOX and CYS-conjugates were obtained by reprocessing UHPLC-HRMS data. Concentration-to-dose ratio (CD; exposure) of CLZ and metabolic ratios (MR; formation) were compared using multivariate linear regression, stratified by smoking status and adjusted for age, sex, and sampling time. Results: Smoking patients comedicated with FLU showed a 3.2-fold higher CLZ CD ratio ( P < 0.0001) and reduced formation of DCL (-38%, P < 0.0001), NOX (-49%, P < 0.0001), CLZ-8-CYS 1+ (-43%, P = 0.0103), and NOX-CYS 1+ (-62%, P = 0.003) compared with smokers receiving CLZ alone. In non-smokers, FLU treatment led to a higher CLZ CD ratio (2.6-fold, P = 0.0012) and reduced formation of DCL (-42%, P = 0.0007), NOX (-52%, P = 0.0009), and NOX-CYS 1+ (-73%, P = 0.0073) compared with the non-smoking controls. Conclusions: This study shows that FLU increases CLZ exposure regardless of smoking status and significantly reduces the formation of metabolites that have been linked to cognition, metabolic side effects, myocarditis, and granulocyte toxicity. Whether FLU alters these clinical outcomes by reducing the metabolic formation needs to be investigated further in controlled studies with access to data on treatment efficacy and side effects.
- Top Cited PapersOpen Access
- 5 January 2026
- Published by Springer Nature in Acta Neurochirurgica
- Vol. 168 (1)
When blood hits the brain: altered glymphatic and dural lymphatic function after surface bleeds
Background: The impact of acute subdural hematoma (aSDH) on measures of glymphatic–meningeal lymphatic function has not previously been reported. We present a descriptive observational study including a small case series—one patient following unilateral aSDH, three following unilateral subarachnoid hemorrhage (SAH), and three control subjects—providing new insights into the differential effects of surface intracranial bleeds. Methods: The magnetic resonance imaging (MRI) contrast agent gadobutrol (0.5 mmol), administered intrathecally, was used as a cerebrospinal fluid (CSF) tracer. Multiphase contrast-enhanced MRI was performed to assess glymphatic tracer enrichment. CSF tracer clearance to blood, serving as a proxy for dural lymphatic function, was estimated using population pharmacokinetic modeling. All hemorrhagic cases involved unilateral bleeds, allowing within-subject comparison between affected and unaffected hemispheres. Results: The series included one patient with aSDH (2.8 months post-event), three patients with unilateral SAH (mean 5.8 months post-event), and three age-matched, near-healthy reference subjects. Compared with controls, glymphatic tracer enrichment 24 h post-injection was slightly increased on the affected hemisphere in the aSDH case, whereas SAH patients showed markedly reduced enrichment on the affected side. Tracer distribution in controls was symmetrical. CSF clearance to blood was notably reduced in the aSDH case compared with references, suggesting impaired dural lymphatic function. Conclusion: This small descriptive series suggests that aSDH and SAH may differentially affect glymphatic and dural lymphatic functions. While glymphatic enrichment appeared only modestly altered after aSDH, it was severely impaired following SAH. In contrast, CSF clearance to blood was markedly reduced in the aSDH case, potentially reflecting compromised dural lymphatic drainage. The limited number of cases prevent broad generalization, but these findings offer novel hypothesis-generating observations that may inform future studies on the effects of surface intracranial hemorrhages on brain clearance pathways.
- 5 January 2026
- Published by Springer Nature in Acta Neurochirurgica
- Vol. 168 (1)
Top Cited PapersOpen AccessWhen blood hits the brain: altered glymphatic and dural lymphatic function after surface bleeds
Background: The impact of acute subdural hematoma (aSDH) on measures of glymphatic–meningeal lymphatic function has not previously been reported. We present a descriptive observational study including a small case series—one patient following unilateral aSDH, three following unilateral subarachnoid hemorrhage (SAH), and three control subjects—providing new insights into the differential effects of surface intracranial bleeds. Methods: The magnetic resonance imaging (MRI) contrast agent gadobutrol (0.5 mmol), administered intrathecally, was used as a cerebrospinal fluid (CSF) tracer. Multiphase contrast-enhanced MRI was performed to assess glymphatic tracer enrichment. CSF tracer clearance to blood, serving as a proxy for dural lymphatic function, was estimated using population pharmacokinetic modeling. All hemorrhagic cases involved unilateral bleeds, allowing within-subject comparison between affected and unaffected hemispheres. Results: The series included one patient with aSDH (2.8 months post-event), three patients with unilateral SAH (mean 5.8 months post-event), and three age-matched, near-healthy reference subjects. Compared with controls, glymphatic tracer enrichment 24 h post-injection was slightly increased on the affected hemisphere in the aSDH case, whereas SAH patients showed markedly reduced enrichment on the affected side. Tracer distribution in controls was symmetrical. CSF clearance to blood was notably reduced in the aSDH case compared with references, suggesting impaired dural lymphatic function. Conclusion: This small descriptive series suggests that aSDH and SAH may differentially affect glymphatic and dural lymphatic functions. While glymphatic enrichment appeared only modestly altered after aSDH, it was severely impaired following SAH. In contrast, CSF clearance to blood was markedly reduced in the aSDH case, potentially reflecting compromised dural lymphatic drainage. The limited number of cases prevent broad generalization, but these findings offer novel hypothesis-generating observations that may inform future studies on the effects of surface intracranial hemorrhages on brain clearance pathways.
- 26 September 2025
- Published by Springer Nature
- p. 259-274
A Non-parametric Optimal Design Algorithm for Population Pharmacokinetics
- 26 September 2025
- Published by Springer Nature
- p. 259-274
A Non-parametric Optimal Design Algorithm for Population Pharmacokinetics
- Open Access
- 9 July 2025
- Published by Wiley in CPT: Pharmacometrics & Systems Pharmacology
- Vol. 14 (9) , 1470-1484
Predicting Drug Transfer Into Human Milk With the Simcyp Simulator: A Contribution From the ConcePTION Project
Physiologically‐based pharmacokinetic (PBPK) modeling can support decision‐making on maternal medication use during breastfeeding. This study aimed to enhance lactation PBPK models in two ways. First, the utility of integrating permeability‐ versus perfusion‐limited distribution to human milk was explored using the Simcyp Simulator. Secondly, for permeability‐limited models, drug‐specific bidirectional intrinsic clearance across the blood‐milk barrier, predicted from drug physicochemical properties, was incorporated into lactation PBPK models. Initially, reference PBPK models were developed and verified against published clinical data. Geometric Mean Fold Error (GMFE; ~accuracy) and Average Fold Error (AFE; ~bias) for these models ranged from 1.13–1.51 and 0.68–1.42, respectively. These verified models were then extended to lactation PBPK models applying either permeability‐ or perfusion‐limited assumptions for drug distribution across the blood‐milk barrier. The lactation PBPK models were applied to predict drug concentrations in human milk and relative infant doses (RID) for 11 small molecule drugs with diverse physicochemical and disposition profiles. The models successfully predicted observed plasma PK, human milk concentration‐time profiles, and milk‐to‐plasma ratios. Nine drugs had RID values below the safety threshold of 25%, while levetiracetam and nevirapine showed relatively higher RIDs (up to 21%). Based on these findings, a decision tree is proposed to guide the selection between permeability‐ or perfusion‐limited distribution models in future lactation PBPK applications using Simcyp. This workflow can be extended beyond the 11 model drugs evaluated, supporting broader infant risk assessment for maternal medication during lactation.
- 9 July 2025
- Published by Wiley in CPT: Pharmacometrics & Systems Pharmacology
- Vol. 14 (9) , 1470-1484
Open AccessPredicting Drug Transfer Into Human Milk With the Simcyp Simulator: A Contribution From the ConcePTION Project
Physiologically‐based pharmacokinetic (PBPK) modeling can support decision‐making on maternal medication use during breastfeeding. This study aimed to enhance lactation PBPK models in two ways. First, the utility of integrating permeability‐ versus perfusion‐limited distribution to human milk was explored using the Simcyp Simulator. Secondly, for permeability‐limited models, drug‐specific bidirectional intrinsic clearance across the blood‐milk barrier, predicted from drug physicochemical properties, was incorporated into lactation PBPK models. Initially, reference PBPK models were developed and verified against published clinical data. Geometric Mean Fold Error (GMFE; ~accuracy) and Average Fold Error (AFE; ~bias) for these models ranged from 1.13–1.51 and 0.68–1.42, respectively. These verified models were then extended to lactation PBPK models applying either permeability‐ or perfusion‐limited assumptions for drug distribution across the blood‐milk barrier. The lactation PBPK models were applied to predict drug concentrations in human milk and relative infant doses (RID) for 11 small molecule drugs with diverse physicochemical and disposition profiles. The models successfully predicted observed plasma PK, human milk concentration‐time profiles, and milk‐to‐plasma ratios. Nine drugs had RID values below the safety threshold of 25%, while levetiracetam and nevirapine showed relatively higher RIDs (up to 21%). Based on these findings, a decision tree is proposed to guide the selection between permeability‐ or perfusion‐limited distribution models in future lactation PBPK applications using Simcyp. This workflow can be extended beyond the 11 model drugs evaluated, supporting broader infant risk assessment for maternal medication during lactation.
- Open Access
A non-parametric optimal design algorithm for population pharmacokinetics
This paper introduces a non-parametric estimation algorithm designed to effectively estimate the joint distribution of model parameters with application to population pharmacokinetics. Our research group has previously developed the non-parametric adaptive grid (NPAG) algorithm, which while accurate, explores parameter space using an ad-hoc method to suggest new support points. In contrast, the non-parametric optimal design (NPOD) algorithm uses a gradient approach to suggest new support points, which reduces the amount of time spent evaluating non-relevant points and by this the overall number of cycles required to reach convergence. In this paper, we demonstrate that the NPOD algorithm achieves similar solutions to NPAG across two datasets, while being significantly more efficient in both the number of cycles required and overall runtime. Given the importance of developing robust and efficient algorithms for determining drug doses quickly in pharmacokinetics, the NPOD algorithm represents a valuable advancement in non-parametric modeling. Further analysis is needed to determine which algorithm performs better under specific conditions.
Open AccessA non-parametric optimal design algorithm for population pharmacokinetics
This paper introduces a non-parametric estimation algorithm designed to effectively estimate the joint distribution of model parameters with application to population pharmacokinetics. Our research group has previously developed the non-parametric adaptive grid (NPAG) algorithm, which while accurate, explores parameter space using an ad-hoc method to suggest new support points. In contrast, the non-parametric optimal design (NPOD) algorithm uses a gradient approach to suggest new support points, which reduces the amount of time spent evaluating non-relevant points and by this the overall number of cycles required to reach convergence. In this paper, we demonstrate that the NPOD algorithm achieves similar solutions to NPAG across two datasets, while being significantly more efficient in both the number of cycles required and overall runtime. Given the importance of developing robust and efficient algorithms for determining drug doses quickly in pharmacokinetics, the NPOD algorithm represents a valuable advancement in non-parametric modeling. Further analysis is needed to determine which algorithm performs better under specific conditions.